Key facts
- InSitu Biologics’s last known valuation is $12.4M (Dec 2025).
- It has raised $11.9M across 3 recorded rounds; the latest was Seed Round ($4.0M) in Nov 2025.
- InSitu Biologics has filed 6 Form Ds with the SEC since 2017, most recently Dec 2025 ($4.0M sold to 29 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for InSitu Biologics
Funding rounds
3 roundsAbout InSitu Biologics
Developer of a drug delivery platform designed to focus on developing new and proprietary treatments using its matrix biohydrogen. The company's platform develops and manufactures implantable time-release products composed of its proprietary tunable and bio-polymeric hydro-gel by using hard particulates in the soft matrix, enabling patients to get relieved from peri-operative regional pain by a long-lasting and long-acting non-opiate painkiller.
- Sector
- Healthcare
- HQ
- Oakdale, MN, United States
- Founded
- 2014
- Employees
- 12
- Website
- insitubiologics.com/
- Ownership
- Privately Held (backing)
InSitu Biologics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InSitu Biologics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InSitu Biologics in its N-PORT filings yet. We sweep new filings monthly.